Abide Therapeutics is categorized under Commercial Biotechnical Research in San Diego, CA and active since 2011.
Abide Therapeutics was established in 2011, and today employs 1 to 4, earning Unknown per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 9999900 by the NAICS.
If you are seeking more information, feel free to contact Alan Ezekowitz at the company’s single location by writing to 3545 John Hopkins Court # 250, San Diego, California CA 92121 or by phoning (858) 404-0812. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Abide Therapeutics |
| Contact Person: | Alan Ezekowitz |
| Address: | 3545 John Hopkins Court # 250, San Diego, California 92121 |
| Phone Number: | (858) 404-0812 |
| Website Address: | abidetx.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 9999900 |
| Share This Business: |
Abide Therapeutics was started in 2011 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 9999900. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Alan Ezekowitz for inquiries that concern Abide Therapeutics by calling the company number (858) 404-0812, as your correspondence is most welcome. Additionally, the physical location of the single location of Abide Therapeutics can be found at the coordinates 32.89217,-117.23794 as well as the street address 3545 John Hopkins Court # 250 in San Diego, California 92121.
For its online presence, you may visit Abide Therapeutics’s website at abidetx.com and engage with its social media outlets through on Twitter and on Facebook.